FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...
Clinical Advisor

Tirzepatide Added to Ixekizumab Improves Outcomes in Patients With PsA

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pum…

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...
MPR

Subcutaneous Lecanemab Starting Dose Under Review for Alzheimer Disease

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...
InvestorsHub on MSN

MannKind shares climb after FDA clears revised Afrezza prescribing label

MannKind Corporation (NASDAQ:MNKD) shares gained 3.5% on Monday after the company said the U.S. Food and Drug Administration ...
Stocktwits on MSN

Why did MNKD stock jump over 7% in pre-market today?

Shares of MannKind Corp. (MNKD) gained more than 7% in pre-market trading on Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing ...